Skip to main content
Funded Studies

Jennifer A. Johnston, PhD

CSO at An2H Discovery

Location: San Francisco, CA United States

Dr. Jennifer Johnston has studied the Ub-proteasome pathway, starting with work on protein folding and substrate degradation by the proteasome with Dr. A. Varshavsky at Caltech. Subsequently, her work with Dr. R. Kopito at Stanford resulted in the discovery and description of aggresomes, the first example of cellular proteostasis, and provided a link between the proteasome pathway and canonical neurodegeneration pathology phenotypes. At Elan Pharmaceuticals, Dr. Johnston directly applied the tenets of aggresome biology, protein folding and cellular proteostasis to basic research and drug discovery for Parkinson's disease and neurodegeneration in general.

In addition to serving as VP Research/Head of Exploratory Research, Dr. Johnston lead the Parkin Project, a drug discovery program focused on the identification of specific small molecule therapeutics that modulate the activity of parkin E3 ligase. Presently, Dr. Johnston is co-founder and CSO of An2H Discovery, a biotech company focused on the modulation of the ubiquitin pathway for critical unmet medical needs in neurology and oncology.


Associated Grants

  • Parkin-activating Small Molecules in a Model of Mitophagy

    2019


  • Identification of Small Molecule Activators of Parkin Protein

    2014


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.